Latest Pharma Insights
People On The Move: Appointments At PK Consumer Health, Orkla Health, GSCF
A round-up of the latest moves in Europe's consumer health sector: Neil Lister named CEO of PK Consumer Health; Patrick Smallcombe appointed chair of Orkla Health's board; Global Self-Care Federation makes four hires to bolster policy, regulatory and operational capabilities.
HBW Insight - September 2, 2026
A round-up of the latest moves in Europe's consumer health sector: Neil Lister named CEO of PK Consumer Health; Patrick Smallcombe appointed chair of Orkla Health's board; Global Self-Care Federation makes four hires to bolster policy, regulatory and operational capabilities.
HBW Insight - September 2, 2026
Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth
Public Company Edition: Moderna sold $2.6bn worth of notes while Jazz sold $1.1bn in notes in private offerings after reporting key data and approvals expected to drive revenue growth. Also, Kazia launched an up to $120m follow-on offering and the SPAC JATT III closed its $69m IPO.
Scrip - September 2, 2026
Public Company Edition: Moderna sold $2.6bn worth of notes while Jazz sold $1.1bn in notes in private offerings after reporting key data and approvals expected to drive revenue growth. Also, Kazia launched an up to $120m follow-on offering and the SPAC JATT III closed its $69m IPO.
Scrip - September 2, 2026
Global Medtech Guidance Tracker: August 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - September 2, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - September 2, 2026
Off-Patent, On Record: A Story Of Patients Fighting For Accessible Cystic Fibrosis Treatment
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner, who share their journey of navigating the patent system to find a generic cystic fibrosis drug.
Generics Bulletin - September 2, 2026
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner, who share their journey of navigating the patent system to find a generic cystic fibrosis drug.
Generics Bulletin - September 2, 2026
Agentic AI And The Repricing Of Healthcare SaaS Models
Healthcare software beat earnings through H1 2026 and sold off anyway. Outcome Capital argues the market is repricing seat-based software, not management — and that healthcare, forced by regulators to codify how it works, is best placed to capture the agentic value replacing it.
In Vivo - September 2, 2026
Healthcare software beat earnings through H1 2026 and sold off anyway. Outcome Capital argues the market is repricing seat-based software, not management — and that healthcare, forced by regulators to codify how it works, is best placed to capture the agentic value replacing it.
In Vivo - September 2, 2026
Apotex Takes Full Control Of Talicia In $53m Deal
After gaining a 30% ownership share in antibacterial combination treatment Talicia through its Cumberland Pharmaceuticals acquisition, Apotex is now taking full control of the product through a deal with RedHill Biopharma that could be worth more than $50m.
Generics Bulletin - September 2, 2026
After gaining a 30% ownership share in antibacterial combination treatment Talicia through its Cumberland Pharmaceuticals acquisition, Apotex is now taking full control of the product through a deal with RedHill Biopharma that could be worth more than $50m.
Generics Bulletin - September 2, 2026
Cabometyx Patent Win Keeps MSN Generic At Bay Until 2030
MSN has failed to convince the Federal Circuit to invalidate three Cabometyx patents, preserving a January 2030 launch barrier, while a separate procedural win leaves another Exelixis patent fight unresolved.
Generics Bulletin - September 2, 2026
MSN has failed to convince the Federal Circuit to invalidate three Cabometyx patents, preserving a January 2030 launch barrier, while a separate procedural win leaves another Exelixis patent fight unresolved.
Generics Bulletin - September 2, 2026
Stock Watch: PD-1s, GLP-1s And Pharma Pairs Trading
Pairs of competing companies like Merck & Co. and BMS, or Lilly and Novo Nordisk, offer a hedge in investors’ portfolios, as long as the historical trends continue and everything stays the same.
Scrip - September 2, 2026
Pairs of competing companies like Merck & Co. and BMS, or Lilly and Novo Nordisk, offer a hedge in investors’ portfolios, as long as the historical trends continue and everything stays the same.
Scrip - September 2, 2026
MHRA May Get Wider Device Licensing Powers As UK Eyes New Regulatory Regime
In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to eventually replace approved bodies.
Medtech Insight - September 2, 2026
In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to eventually replace approved bodies.
Medtech Insight - September 2, 2026
EU Project Will Digitize Conformity Assessment To Free Up Manufacturer Resources
Team-NB heads consortium to develop open-source, single-entry-point digital assessment framework to replace “onerous” existing system.
Medtech Insight - September 2, 2026
Team-NB heads consortium to develop open-source, single-entry-point digital assessment framework to replace “onerous” existing system.
Medtech Insight - September 2, 2026
Eucerin’s Probiom8 May Mark New Era In Acne Treatment
Beiersdorf reveals its highly anticipated TopiC.A active ingredient for fighting acne is launching in a regimen under the Eucerin brand.
HBW Insight - September 2, 2026
Beiersdorf reveals its highly anticipated TopiC.A active ingredient for fighting acne is launching in a regimen under the Eucerin brand.
HBW Insight - September 2, 2026
Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth
Public Company Edition: Moderna sold $2.6bn worth of notes while Jazz sold $1.1bn in notes in private offerings after reporting key data and approvals expected to drive revenue growth. Also, Kazia launched an up to $120m follow-on offering and the SPAC JATT III closed its $69m IPO.
Scrip - September 2, 2026
Public Company Edition: Moderna sold $2.6bn worth of notes while Jazz sold $1.1bn in notes in private offerings after reporting key data and approvals expected to drive revenue growth. Also, Kazia launched an up to $120m follow-on offering and the SPAC JATT III closed its $69m IPO.
Scrip - September 2, 2026
Stock Watch: PD-1s, GLP-1s And Pharma Pairs Trading
Pairs of competing companies like Merck & Co. and BMS, or Lilly and Novo Nordisk, offer a hedge in investors’ portfolios, as long as the historical trends continue and everything stays the same.
Scrip - September 2, 2026
Pairs of competing companies like Merck & Co. and BMS, or Lilly and Novo Nordisk, offer a hedge in investors’ portfolios, as long as the historical trends continue and everything stays the same.
Scrip - September 2, 2026
Global Medtech Guidance Tracker: August 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - September 2, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - September 2, 2026
MHRA May Get Wider Device Licensing Powers As UK Eyes New Regulatory Regime
In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to eventually replace approved bodies.
Medtech Insight - September 2, 2026
In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to eventually replace approved bodies.
Medtech Insight - September 2, 2026
EU Project Will Digitize Conformity Assessment To Free Up Manufacturer Resources
Team-NB heads consortium to develop open-source, single-entry-point digital assessment framework to replace “onerous” existing system.
Medtech Insight - September 2, 2026
Team-NB heads consortium to develop open-source, single-entry-point digital assessment framework to replace “onerous” existing system.
Medtech Insight - September 2, 2026
People On The Move: Appointments At PK Consumer Health, Orkla Health, GSCF
A round-up of the latest moves in Europe's consumer health sector: Neil Lister named CEO of PK Consumer Health; Patrick Smallcombe appointed chair of Orkla Health's board; Global Self-Care Federation makes four hires to bolster policy, regulatory and operational capabilities.
HBW Insight - September 2, 2026
A round-up of the latest moves in Europe's consumer health sector: Neil Lister named CEO of PK Consumer Health; Patrick Smallcombe appointed chair of Orkla Health's board; Global Self-Care Federation makes four hires to bolster policy, regulatory and operational capabilities.
HBW Insight - September 2, 2026
Eucerin’s Probiom8 May Mark New Era In Acne Treatment
Beiersdorf reveals its highly anticipated TopiC.A active ingredient for fighting acne is launching in a regimen under the Eucerin brand.
HBW Insight - September 2, 2026
Beiersdorf reveals its highly anticipated TopiC.A active ingredient for fighting acne is launching in a regimen under the Eucerin brand.
HBW Insight - September 2, 2026
Off-Patent, On Record: A Story Of Patients Fighting For Accessible Cystic Fibrosis Treatment
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner, who share their journey of navigating the patent system to find a generic cystic fibrosis drug.
Generics Bulletin - September 2, 2026
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner, who share their journey of navigating the patent system to find a generic cystic fibrosis drug.
Generics Bulletin - September 2, 2026
Apotex Takes Full Control Of Talicia In $53m Deal
After gaining a 30% ownership share in antibacterial combination treatment Talicia through its Cumberland Pharmaceuticals acquisition, Apotex is now taking full control of the product through a deal with RedHill Biopharma that could be worth more than $50m.
Generics Bulletin - September 2, 2026
After gaining a 30% ownership share in antibacterial combination treatment Talicia through its Cumberland Pharmaceuticals acquisition, Apotex is now taking full control of the product through a deal with RedHill Biopharma that could be worth more than $50m.
Generics Bulletin - September 2, 2026
Cabometyx Patent Win Keeps MSN Generic At Bay Until 2030
MSN has failed to convince the Federal Circuit to invalidate three Cabometyx patents, preserving a January 2030 launch barrier, while a separate procedural win leaves another Exelixis patent fight unresolved.
Generics Bulletin - September 2, 2026
MSN has failed to convince the Federal Circuit to invalidate three Cabometyx patents, preserving a January 2030 launch barrier, while a separate procedural win leaves another Exelixis patent fight unresolved.
Generics Bulletin - September 2, 2026
Agentic AI And The Repricing Of Healthcare SaaS Models
Healthcare software beat earnings through H1 2026 and sold off anyway. Outcome Capital argues the market is repricing seat-based software, not management — and that healthcare, forced by regulators to codify how it works, is best placed to capture the agentic value replacing it.
In Vivo - September 2, 2026
Healthcare software beat earnings through H1 2026 and sold off anyway. Outcome Capital argues the market is repricing seat-based software, not management — and that healthcare, forced by regulators to codify how it works, is best placed to capture the agentic value replacing it.
In Vivo - September 2, 2026